News and Trends 5 Apr 2023
InflaRx receives emergency use authorization for critically ill COVID-19 patients treatment
InflaRx N.V., a German company developing anti-inflammatory therapeutics by targeting the complement system, has announced that Gohibic (vilobelimab) has been granted an Emergency Use Authorization (EUA) by the U.S. Food…